Alyeska Investment Group
VXRT

Alyeska Investment Group’s Vaxart VXRT Stock Holding History

Alyeska Investment Group’s Portfolio VXRT Stock Details VXRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,250,000
Closed -$834K – 695
2024
Q2 		$834K Buy
+1,250,000
New +$1.04M ﹤0.01% 472

Other funds holding VXRT

SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Alyeska Investment Group's VXRT Position: Q3 2024 in Review

Alyeska Investment Group sold out of Vaxart (VXRT) in Q3 2024, closing a stake of 1,250,000 shares — an estimated $834K sold.

Alyeska Investment Group first reported a position in VXRT in Q2 2024 and held it in 1 quarter. The position peaked at $834K in Q2 2024. 100 funds tracked by Wall St. Rank hold VXRT as of Q3 2024.

  • Alyeska Investment Group reported no remaining Vaxart position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 1,250,000 Vaxart shares in Q3 2024, an estimated $834K.
  • Alyeska Investment Group first reported a position in Vaxart in Q2 2024 and held it in 1 quarter.
  • Alyeska Investment Group's Vaxart position peaked at $834K in Q2 2024.
  • 100 funds tracked by Wall St. Rank held Vaxart as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.